While computers have long since surpassed the capabilities of the human brain in certain areas, people have continued to outperform machines at visual object recognition. Now though, computers may be starting to catch up--and the advance has implications for our understanding of the human brain.
Microchips Biotech says it's ready to send its delivery technology out into the world, this week announcing it has completed development and clinical demonstration of the drug-delivering implant.
Two different groups of investigators say they've found a way to identify a large group of patients that are characterized by a very high risk of developing blood cancers--and their discovery could pave the way to a new treatment approach in oncology.
As the med tech industry casts its eye toward quick, point-of-care diagnostics, scientists at MIT are teaming up with physicians from Harvard Medical School to create new technology that could help distinguish between acute emphysema and heart failure by measuring an individual's breath.
With small but prestigious contributions from the scientific community, SQZ Biotech is looking to launch its CellSqueeze platform to be used in commercial applications.
Portal Instruments, a new Boston-based company, secured $11 million for its computerized needle-free drug delivery system via a Series A funding round led by Sanofi, Boston-based VC PBJ Capital and a major medical device company. It became only the third company to receive funding under Sanofi's Sunrise Initiative for early stage companies.
A pill coated with tiny needles may help improve oral treatments, according to researchers. When swallowed, the pill delivers large molecules such as insulin into the lining of the stomach and does so more efficiently than an injection under the skin.
MIT scientists have employed a harmless version of the anthrax causing bacteria for drug delivery purposes, using it to insert drugs known as antibody mimics inside cells in the fight against cancer.
Malaria parasites produce waste products as they spread in the blood. Those parasitic discharges may give scientists an ideal diagnostic biomarker to help spot the infection and determine how serious it is, researchers have found.
A team of MIT researchers successfully tested a thin-film drug delivery system enabling steady, sustained release of medication for about 14 months, a scientific advancement with major commercial implications.